160 related articles for article (PubMed ID: 38637560)
21. The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic.
Frankell AM; Jammula S; Li X; Contino G; Killcoyne S; Abbas S; Perner J; Bower L; Devonshire G; Ococks E; Grehan N; Mok J; O'Donovan M; MacRae S; Eldridge MD; Tavaré S; ; Fitzgerald RC
Nat Genet; 2019 Mar; 51(3):506-516. PubMed ID: 30718927
[TBL] [Abstract][Full Text] [Related]
22. Integrated genomics and comprehensive validation reveal drivers of genomic evolution in esophageal adenocarcinoma.
Kumar S; Buon L; Talluri S; Roncador M; Liao C; Zhao J; Shi J; Chakraborty C; Gonzalez G; Tai YT; Prabhala R; Samur MK; Munshi NC; Shammas MA
Commun Biol; 2021 May; 4(1):617. PubMed ID: 34031527
[TBL] [Abstract][Full Text] [Related]
23. Comparison of cancer-associated genetic abnormalities in columnar-lined esophagus tissues with and without goblet cells.
Bandla S; Peters JH; Ruff D; Chen SM; Li CY; Song K; Thoms K; Litle VR; Watson T; Chapurin N; Lada M; Pennathur A; Luketich JD; Peterson D; Dulak A; Lin L; Bass A; Beer DG; Godfrey TE; Zhou Z
Ann Surg; 2014 Jul; 260(1):72-80. PubMed ID: 24509200
[TBL] [Abstract][Full Text] [Related]
24. LKB1 inactivation occurs in a subset of esophageal adenocarcinomas and is sufficient to drive tumor cell proliferation.
Whitsett TG; Mittal SK; Eschbacher JM; Carson VM; Smith MA; Bremner RM; Inge LJ
J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1891-1899. PubMed ID: 29370903
[TBL] [Abstract][Full Text] [Related]
25. Impact of mutations in Toll-like receptor pathway genes on esophageal carcinogenesis.
Fels Elliott DR; Perner J; Li X; Symmons MF; Verstak B; Eldridge M; Bower L; O'Donovan M; Gay NJ; ; Fitzgerald RC
PLoS Genet; 2017 May; 13(5):e1006808. PubMed ID: 28531216
[TBL] [Abstract][Full Text] [Related]
26. Racial disparities in esophageal cancer treatment and outcomes.
Greenstein AJ; Litle VR; Swanson SJ; Divino CM; Packer S; McGinn TG; Wisnivesky JP
Ann Surg Oncol; 2008 Mar; 15(3):881-8. PubMed ID: 17987341
[TBL] [Abstract][Full Text] [Related]
27. Germline variation in the insulin-like growth factor pathway and risk of Barrett's esophagus and esophageal adenocarcinoma.
Dighe SG; Chen J; Yan L; He Q; Gharahkhani P; Onstad L; Levine DM; Palles C; Ye W; Gammon MD; Iyer PG; Anderson LA; Liu G; Wu AH; Dai JY; Chow WH; Risch HA; Lagergren J; Shaheen NJ; Bernstein L; Corley DA; Prenen H; deCaestecker J; MacDonald D; Moayyedi P; Barr H; Love SB; Chegwidden L; Attwood S; Watson P; Harrison R; Ott K; Moebus S; Venerito M; Lang H; Mayershofer R; Knapp M; Veits L; Gerges C; Weismüller J; Gockel I; Vashist Y; Nöthen MM; Izbicki JR; Manner H; Neuhaus H; Rösch T; Böhmer AC; Hölscher AH; Anders M; Pech O; Schumacher B; Schmidt C; Schmidt T; Noder T; Lorenz D; Vieth M; May A; Hess T; Kreuser N; Becker J; Ell C; Ambrosone CB; Moysich KB; MacGregor S; Tomlinson I; Whiteman DC; Jankowski J; Schumacher J; Vaughan TL; Madeleine MM; Hardie LJ; Buas MF
Carcinogenesis; 2021 Apr; 42(3):369-377. PubMed ID: 33300568
[TBL] [Abstract][Full Text] [Related]
28. Targeted next-generation sequencing of commonly mutated genes in esophageal adenocarcinoma patients with long-term survival.
Visser E; Franken IA; Brosens LAA; de Leng WWJ; Strengman E; Offerhaus JA; Ruurda JP; van Hillegersberg R
Dis Esophagus; 2017 Sep; 30(9):1-8. PubMed ID: 28859360
[TBL] [Abstract][Full Text] [Related]
29. Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome.
Kim SM; Park YY; Park ES; Cho JY; Izzo JG; Zhang D; Kim SB; Lee JH; Bhutani MS; Swisher SG; Wu X; Coombes KR; Maru D; Wang KK; Buttar NS; Ajani JA; Lee JS
PLoS One; 2010 Nov; 5(11):e15074. PubMed ID: 21152079
[TBL] [Abstract][Full Text] [Related]
30. Upregulation of insulin-like growth factor II mRNA-binding protein 3 (IMP3) has negative prognostic impact on early invasive (pT1) adenocarcinoma of the esophagus.
Plum PS; Ulase D; Bollschweiler E; Chon SH; Berlth F; Zander T; Alakus H; Hölscher AH; Bruns CJ; Schallenberg S; Quaas A; Loeser H
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1731-1739. PubMed ID: 29974234
[TBL] [Abstract][Full Text] [Related]
31. Whole genome expression array profiling highlights differences in mucosal defense genes in Barrett's esophagus and esophageal adenocarcinoma.
Nancarrow DJ; Clouston AD; Smithers BM; Gotley DC; Drew PA; Watson DI; Tyagi S; Hayward NK; Whiteman DC; ;
PLoS One; 2011; 6(7):e22513. PubMed ID: 21829465
[TBL] [Abstract][Full Text] [Related]
32. Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance.
Secrier M; Li X; de Silva N; Eldridge MD; Contino G; Bornschein J; MacRae S; Grehan N; O'Donovan M; Miremadi A; Yang TP; Bower L; Chettouh H; Crawte J; Galeano-Dalmau N; Grabowska A; Saunders J; Underwood T; Waddell N; Barbour AP; Nutzinger B; Achilleos A; Edwards PA; Lynch AG; Tavaré S; Fitzgerald RC;
Nat Genet; 2016 Oct; 48(10):1131-41. PubMed ID: 27595477
[TBL] [Abstract][Full Text] [Related]
33. Incidence Trends of Esophageal and Gastric Cancer Subtypes by Race, Ethnicity, and Age in the United States, 1997-2014.
Islami F; DeSantis CE; Jemal A
Clin Gastroenterol Hepatol; 2019 Feb; 17(3):429-439. PubMed ID: 29902641
[TBL] [Abstract][Full Text] [Related]
34. Potential Clinical Utility of a Targeted Circulating Tumor DNA Assay in Esophageal Adenocarcinoma.
Cabalag CS; Yates M; Corrales MB; Yeh P; Wong SQ; Zhang BZ; Fujihara KM; Chong L; Hii MW; Dawson SJ; Phillips WA; Duong CP; Clemons NJ
Ann Surg; 2022 Aug; 276(2):e120-e126. PubMed ID: 35737908
[TBL] [Abstract][Full Text] [Related]
35. Next-generation sequencing of endoscopic biopsies identifies ARID1A as a tumor-suppressor gene in Barrett's esophagus.
Streppel MM; Lata S; DelaBastide M; Montgomery EA; Wang JS; Canto MI; Macgregor-Das AM; Pai S; Morsink FH; Offerhaus GJ; Antoniou E; Maitra A; McCombie WR
Oncogene; 2014 Jan; 33(3):347-57. PubMed ID: 23318448
[TBL] [Abstract][Full Text] [Related]
36. Trends in Esophageal Cancer Mortality and Stage at Diagnosis by Race and Ethnicity in the United States.
Corona E; Yang L; Esrailian E; Ghassemi KA; Conklin JL; May FP
Cancer Causes Control; 2021 Aug; 32(8):883-894. PubMed ID: 34003396
[TBL] [Abstract][Full Text] [Related]
37. Underuse of Surgery Accounts for Racial Disparities in Esophageal Cancer Survival Times: A Matched Cohort Study.
Dong J; Gu X; El-Serag HB; Thrift AP
Clin Gastroenterol Hepatol; 2019 Mar; 17(4):657-665.e13. PubMed ID: 30036643
[TBL] [Abstract][Full Text] [Related]
38. Detection of Mutations in Barrett's Esophagus Before Progression to High-Grade Dysplasia or Adenocarcinoma.
Stachler MD; Camarda ND; Deitrick C; Kim A; Agoston AT; Odze RD; Hornick JL; Nag A; Thorner AR; Ducar M; Noffsinger A; Lash RH; Redston M; Carter SL; Davison JM; Bass AJ
Gastroenterology; 2018 Jul; 155(1):156-167. PubMed ID: 29608884
[TBL] [Abstract][Full Text] [Related]
39. Descriptive epidemiology of esophageal carcinoma in the Ohio Cancer Registry.
Cummings LC; Cooper GS
Cancer Detect Prev; 2008; 32(1):87-92. PubMed ID: 18406068
[TBL] [Abstract][Full Text] [Related]
40. Isoforms of RNF128 Regulate the Stability of Mutant P53 in Barrett's Esophageal Cells.
Ray D; Ray P; Ferrer-Torres D; Wang Z; Nancarrow D; Yoon HW; San Martinho M; Hinton T; Owens S; Thomas D; Jiang H; Lawrence TS; Lin J; Lagisetty K; Chang AC; Beer DG
Gastroenterology; 2020 Feb; 158(3):583-597.e1. PubMed ID: 31715145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
